← FDA DRUG APPROVALS

FDA ANDA · ANDA040506

ETHOSUXIMIDE

Sponsor: CHARTWELL RX

APPLICATION
ANDA040506
TYPE
ANDA
ORIGINAL APPROVAL
2003-12-22
LATEST ACTION
2014-01-10
ROUTE
ORAL
DOSAGE FORM
SYRUP
MARKETING STATUS
Prescription

Products

ETHOSUXIMIDEPrescription
ETHOSUXIMIDE 250MG/5ML · SYRUP · ORAL

Approval history

2014-01-10Labeling · Supplement 4 · standardAP
2009-12-10Labeling · Supplement 3AP
2008-08-15Labeling · Supplement 2AP
2003-12-22OriginalAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →